EA-230 90mg/kg/hour for coronary artery disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Jan 2026: Trial registered, NCT07357675
  2. 29 Oct 2026: Trial started, NCT07357675

The trials

NCT07357675: A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.

State
Under way
Phase
Phase 3
People
300 planned
Started
29 Oct 2026
Primary completion
1 Oct 2027
Arms
EA-230 90mg/kg/hour
Results
None posted
  1. 22 Jan 2026: Trial registered
  2. 29 Oct 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.